Utah is currently home to 1224 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Salt Lake City, Murray, Ogden and West Jordan. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
NCT06395519
Recruiting
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2024
Locations: START Center for Cancer Care - Mountain Region, Salt Lake City, Utah
Conditions: Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Epithelial Ovarian Cancer, BRCA2 Mutation, ER+ Breast Cancer, Castrate Resistant Prostate Cancer, BRCA1 Mutation, BRCA Mutation, Endometrial Cancer, Colorectal Cancer, Gastric Cancer
Register for Updates
5-HTP and Creatine for Depression R33 Phase
NCT05895747
Recruiting
This is a three-armed clinical trial examining the effect of 5-hydroxytryptophan and creatine monohydrate as augmenting agents for the treatment of depression. Subjects will be randomized between 5-HTP 100mg BID + creatine 5g daily, 5-HTP 200mg BID + creatine 10g daily, vs double placebo, for 8 weeks. The ability of the interventions to affect biomarkers associated with depression will be assessed using brain phosphorus magnetic resonance spectroscopy, functional connectivity imaging, and plasma... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/01/2024
Locations: University of Utah Department of Psychiatry, Salt Lake City, Utah
Conditions: Major Depressive Disorder
Register for Updates
Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT05613894
Recruiting
This is an open-label, phase 1b dose-escalation study of cabozantinib in combination with 177Lu-PSMA-617 in subjects with mCRPC. The primary hypothesis is that cabozantinib with 177Lu-PSMA will be safe and have efficacy in patients with mCRPC. The dose-escalation phase (Part 1) will assess the rate of dose-limiting toxicities (DLTs) during the DLT evaluation period and identify the MTD and/or recommended dose and schedule for the subsequent expansion phase (Part 2).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/01/2024
Locations: Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah
Conditions: Metastatic Castration-resistant Prostate Cancer
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: American Fork Hospital / Huntsman Intermountain Cancer Center, American Fork, Utah
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
A Phase 2 Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain (CYPRESS)
NCT05895552
Recruiting
This is a 2-part, randomized, placebo-controlled, double-blind, Phase 2 study to evaluate the safety, tolerability, efficacy, and pharmacokinetics (PK) of RTA 901 in qualified participants with Diabetic Peripheral Neuropathic Pain (DPNP). Each study part will be randomized into 3 treatment arms; 2 different doses of RTA 901 and RTA 901-maching placebo. The doses of RTA 901 in Part 2 will be selected based on the Exposure-Response (E-R) analyses of data from Part 1. A total of 384 participants wi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/28/2024
Locations: Velocity Clinical Research, Salt Lake City, West Jordan, Utah
Conditions: Diabetic Peripheral Neuropathic Pain
Register for Updates
Exercise and NO in HFrEF
NCT03136029
Recruiting
Heart disease is the leading cause of death in the United States, accounting for one in every four deaths in 2010 and costing over $300 billion annually in health care, medication, and lost productivity. Heart failure with a reduced ejection fraction (HFrEF), a clinical syndrome that develops as a consequence of heart disease, now affects almost 6 million Americans. Within the VA Health Care System, HFrEF hospital admission rates continue to rise, and remain the number one reason for discharge f... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah
Conditions: Heart Failure With Reduced Ejection Fraction
Register for Updates
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
NCT03053193
Recruiting
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: Ogden Regional Cancer Center, Ogden, Utah
Conditions: Breast Cancer
Register for Updates
Mechanisms of Rumination Change in Adolescent Depression
NCT03859297
Recruiting
This study will evaluate whether a newer treatment, rumination-focused cognitive behavioral treatment, which includes mindfulness and can be used to reduce ruminative habits, change ways in which key brain regions interact with each other (e.g.., often called connectivity), and whether these changes in habits and brain connectivity can reduce the risk for recurrence of depression in the next two years.
Gender:
ALL
Ages:
Between 14 years and 17 years
Trial Updated:
06/25/2024
Locations: University of Utah, Salt Lake City, Utah
Conditions: Major Depressive Disorder, Mood Disorders
Register for Updates
Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Metastatic Colorectal Cancer
NCT06358677
Recruiting
The goal of this clinical trial is to learn if using topical tretinoin will help patients with colorectal cancer who are experiencing an acneiform rash as a side effect of their treatment. Researchers will compare the use of tretinoin on one side of the face to the use of a placebo on the other side of the face to see if there is an impact.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah
Conditions: Metastatic Colon Cancer, Metastatic Rectum Cancer
Register for Updates
HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants
NCT04177914
Recruiting
Hydrocephalus is a potentially debilitating neurological condition that primarily affects babies under a year of age and has traditionally been treated by inserting a shunt between the brain and the abdomen. A newer endoscopic procedure offers hope of shunt- free treatment that may reduce complications over a child's life, but it is not clear if the endoscopic procedure results in similar intellectual outcome as shunt. Therefore, the investigators propose a randomized trial to compare intellectu... Read More
Gender:
ALL
Ages:
Between 1 day and 104 weeks
Trial Updated:
06/20/2024
Locations: Primary Children's Hospital, Salt Lake City, Utah
Conditions: Hydrocephalus
Register for Updates
Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease
NCT02402660
Recruiting
The purpose of this study is to determine the long term safety and tolerability of ALK-001 (C20-D3-retinyl acetate), and to explore the effects of ALK-001 on the progression of Stargardt disease in patients between the ages of 8 and 70 years old. Funding Source - FDA OOPD
Gender:
ALL
Ages:
Between 8 years and 70 years
Trial Updated:
06/18/2024
Locations: University of Utah - Moran Eye Institute, Salt Lake City, Utah
Conditions: Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)
Register for Updates
Expanded Indications in the Pediatric BONEBRIDGE Population
NCT05615649
Recruiting
This study will assess safety and efficacy of the MED-EL BONEBRIDGE Bone Conduction Implant in children under 12 years old with conductive or mixed hearing loss.
Gender:
ALL
Ages:
Between 3 years and 12 years
Trial Updated:
06/17/2024
Locations: University of Utah Health/Primary Children's Hospital, Salt Lake City, Utah
Conditions: Hearing Loss, Conductive, Hearing Loss, Mixed
Register for Updates